Objective To investigate the clinical value of the plasma D-dimer detection in patients with non-small cell lung cancer ( NSCLC) .Methods The plasma D-dimer levels of 47 NSCLC patients and 66 healthy subjects were detected by immuno-nephelometry .The relationships between plasma D-dimer level and the clinical stage , pathological type and lymph node metastasis of NSCLC patients were analyzed .The D-dimer levels of NSCLC patients before and after chemotherapy were compared .The relationship between the D-dimer and the efficacy of chemotherapy was analyzed . Results The levels of plasma D-dimer were significantly higher in NSCLC patients [0.96(0.63~1.35) mg/L] than in the healthy subjects [0.34(0.17 ~0.39) mg/L,P<0.01].The levels of plasma D-dimer in different clinical stage groups and pathological type groups were statistically significant ( P<0.05 );and it had relationship with lymph node metastasis (r=0.609, P<0.05).After chemotherapy, the levels of D-dimer in effective groups ( contain complete response group and partial response group ) were significantly decreased (P<0.05).There were no significant changes in stability group (P>0.05) and significant higher in progress group (P<0.05).Conclusions The plasma D-dimer has clinical significance in the clinical stage , pathological type and lymph node metastasis in NSCLC patients , and can be used as an effective indicator to evaluate the efficacy of chemotherapy .%目的：探讨血浆D-二聚体在非小细胞肺癌（ NSCLC ）患者中的临床价值。方法采用免疫比浊法检测47例NSCLC患者及66名健康人的血浆D-二聚体水平，对D-二聚体与NSCLC临床分期、病理分型和淋巴转移之间的关系进行分析；通过比较NSCLC患者化疗前后D-二聚体的水平，探讨其与化疗疗效之间的关系。结果NSCLC患者血浆D-二聚体水平[0．96（0．63～1．35） mg／L]较健康对照组[（0．34（0．17～0．39） mg／L]显著升高（P＜0．01）；不同临床分期和病理分型患者 D-二聚体水平差异均有统计学意义（P＜0．05）；也与淋巴转移存在相关性（r＝0．609，P＜0．05）。化疗后，有效组（完全缓解及部分缓解）的血浆D-二聚体水平较化疗前明显下降（P＜0．05）；稳定组无明显变化（P＞0．05）；进展组明显升高（P＜0．05）。结论血浆 D-二聚体在NSCLC患者的临床分期、病理分型和淋巴转移中具有一定的临床意义，并可作为评估化疗疗效的有效指标。
展开▼
